Take a look at our previous reports:

Half-year financial report 2023

Portfolio

A woman in a laboratory (photo)

The following chart provides an overview of our lead product and product candidates currently in development as of the date of the publication of this report.

Portfolio (graph)
Filgotinib is approved for RA and UC in EU, Great Britain and Japan. AxSpA, axial spondyloarthritis; CLL, chronic lymphocytic leukemia; DM, dermatomyositis; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; UC, ulcerative colitis
Portfolio (graph)
Filgotinib is approved for RA and UC in EU, Great Britain and Japan. AxSpA, axial spondyloarthritis; CLL, chronic lymphocytic leukemia; DM, dermatomyositis; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; UC, ulcerative colitis
Development
All activities required to bring a new drug to the market. This includes preclinical and clinical development research, chemical and pharmaceutical development and regulatory filings of product candidates
Product candidate
Substance that has satisfied the requirements of early preclinical testing and has been selected for development, starting with formal preclinical safety evaluation followed by clinical testing for the treatment of a certain disorder in humans